Jump to content

2,5-Dimethoxy-4-amylamphetamine

From Wikipedia, the free encyclopedia
(Redirected from DOAM (drug))
DOAM
Clinical data
Other namesDOAM; 2,5-Dimethoxy-4-amylamphetamine; 4-Amyl-2,5-dimethoxyamphetamine; 2,5-Dimethoxy-4-pentylamphetamine; 4-Pentyl-2,5-dimethoxyamphetamine
Routes of
administration
Oral
Drug classSerotonin 5-HT2 receptor agonist
Identifiers
  • 1-(2,5-dimethoxy-4-pentylphenyl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC16H27NO2
Molar mass265.397 g·mol−1
3D model (JSmol)
  • CCCCCC1=CC(OC)=C(CC(C)N)C=C1OC
  • InChI=1S/C16H27NO2/c1-5-6-7-8-13-10-16(19-4)14(9-12(2)17)11-15(13)18-3/h10-12H,5-9,17H2,1-4H3 checkY
  • Key:VLJORLCVOAUUKM-UHFFFAOYSA-N checkY
  (verify)

2,5-Dimethoxy-4-amylamphetamine (DOAM), also known as 2,5-dimethoxy-4-pentylamphetamine, is a lesser-known serotonin receptor agonist of the amphetamine and DOx families.

Effects

[edit]

DOAM was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 10 mg, and the duration is unknown. DOAM produces a bare threshold and tenseness.

Pharmacology

[edit]

As the 4-alkyl chain length is increased from shorter homologues such as DOM, DOET and DOPR which are all potent hallucinogens, the 5-HT2 binding affinity increases, rising to a maximum with the 4-(n-hexyl) derivative before falling again with even longer chains, but compounds with chain length longer than n-propyl, or with other bulky groups such as isopropyl, t-butyl or γ-phenylpropyl at the 4- position, fail to substitute for hallucinogens in animals or produce hallucinogenic effects in humans, suggesting these have low efficacy and are thus antagonists or partial agonists at the 5-HT2A receptor.[1][2][3][4] However, DOAM has been found to be a moderate-efficacy partial agonist of the serotonin 5-HT2A receptor.[5] Hence, the reasons for the lack of psychedelic effects with DOAM remain unknown.[5]

See also

[edit]

References

[edit]
  1. ^ Shulgin AT, Dyer DC (December 1975). "Psychotomimetic phenylisopropylamines. 5. 4-Alkyl-2,5-dimethoxyphenylisopropylamines". Journal of Medicinal Chemistry. 18 (12): 1201–4. doi:10.1021/jm00246a006. PMID 1195275.
  2. ^ Seggel MR, Yousif MY, Lyon RA, Titeler M, Roth BL, Suba EA, Glennon RA (March 1990). "A structure-affinity study of the binding of 4-substituted analogues of 1-(2,5-dimethoxyphenyl)-2-aminopropane at 5-HT2 serotonin receptors". Journal of Medicinal Chemistry. 33 (3): 1032–6. doi:10.1021/jm00165a023. PMID 2308135.
  3. ^ Dowd CS, Herrick-Davis K, Egan C, DuPre A, Smith C, Teitler M, Glennon RA (August 2000). "1-[4-(3-Phenylalkyl)phenyl]-2-aminopropanes as 5-HT(2A) partial agonists". Journal of Medicinal Chemistry. 43 (16): 3074–84. doi:10.1021/jm9906062. PMID 10956215.
  4. ^ Kruegel AC. Phenalkylamines and Methods of Making and Using the Same. Patent WO 2022/192781
  5. ^ a b Luethi, Dino; Rudin, Deborah; Hoener, Marius C.; Liechti, Matthias E. (2022). "Monoamine Receptor and Transporter Interaction Profiles of 4-Alkyl-Substituted 2,5-Dimethoxyamphetamines" (PDF). The FASEB Journal. 36 (S1). doi:10.1096/fasebj.2022.36.S1.R2691. ISSN 0892-6638.
[edit]